

Global respiratory complications market to exceed \$30 billion by 2022, despite limited pipeline

Écrit par GBI Research
Jeudi, 09 Mars 2017 19:41 -

GlobalData»

The respiratory complications market is set to grow from \$21.8 billion in 2015 to \$30.2 billion by 2022, m

The company's [latest report](#) states that, despite a small late-stage pipeline, the space will see a

Yasser Mushtaq, Senior Analyst for GBI Research, explains: "There are few drugs that generate subst

Several recently approved drugs are expected to unlock a substantial degree of commercial potential w

The most notable of these are Uptravi (selexipag) and Opsumit (macitentan), both marketed by Actelion

Mushtaq continues: "Pfizer is expected to maintain its position as market leader throughout the entire f

"Smaller biopharmaceutical firms, such as Actelion, Novavax, and United Therapeutics, also feature pr